Brief: Suven Life Sciences Doses First Subjects In Phase-1 Trial Of Suvn-I6107
08/01/2025 08:46
Jan 8 (Reuters) - Suven Life Sciences Ltd SUVP.NS :
* SUVEN LIFE SCIENCES LTD - DOSES FIRST SUBJECTS IN PHASE-1
TRIAL
OF SUVN-I6107
Source text: ID:nBSE5zSLCp
Further company coverage: SUVP.NS
((reuters.briefs@thomsonreuters.com;))
Recent news on Suven Life Sciences
See all newsBrief: Suven Life Sciences Completes Phase-1 Study Of SUVN-I6107, Advances To Phase-2
Brief: Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study
Brief: Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences Says First Patient Randomized In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences March-Quarter Consol Net Loss 439.4 Million Rupees